Equity / Investment · GCC · Announced 9 Nov 2026
Saudi Industrial Development Fund → Avalon Pharma
Avalon Pharma signed a SAR 60 million (about US$16 million) two-year working-capital facility with the Saudi Industrial Development Fund, secured on its Avalon-2 plant, central warehouse and a promissory note.
Parties: Saudi Industrial Development Fund (SIDF) (Saudi Arabia) → Avalon Pharma (Saudi Arabia)
- Deal type
- Equity / Investment
- Value
- $16m
- Territory
- Saudi Arabia
- Therapeutic area
- Multi-therapy
- Asset
- Working capital credit facility
- Announced
- 9 Nov 2026
Our analysis
Why this matters
Middle East Pharmaceutical Industries Co. (Avalon Pharma, Tadawul: 4016) announced on 9 November 2026 that it has signed a credit facility agreement with the Saudi Industrial Development Fund (SIDF). The facility is SAR 60 million (about US$16 million), runs for two Gregorian years from the date the funds are received, and is for working capital. The company gives 8 November 2026 as the date the financing was obtained and states that no related parties are involved.
The money is not tied to a specific plant or capex project. It funds the day-to-day cycle of a generics manufacturer: raw materials and APIs, inventory, and the gap between paying suppliers and collecting from customers. That cycle has become heavier for Saudi producers as they add licensed products and serve long public-sector payment chains.
The full analysis is free to read with a work email on this page.